Gilead Sciences Inc
NASDAQ: GILD
$92.59
-$1.76 (-1.9%)
Real Time Data Delayed 15 Min.
GILD Articles
Here are some of today’s top stories affecting key drug and biotech stocks, accompanied with links through to more detailed information and analysis at BioHealthInvestor.com: New short-interest...
Published:
Novartis AG (NYSE: NVS) shares are at session highs and well of the lows of the day in the early afternoon Thursday after Japan okayed one of the company’s human growth hormones, the first approval...
Published:
Monday is looking like a SWINE FLU speculative flu stock stock bonanza, and we want to caution about some of the lessons of scares in the past of SARS, bird flu, Mad Cow, and even hoof & mouth as...
Published:
Last Updated:
Gilead Sciences, Inc. (Nasdaq: GILD) has agreed to buy CV Therapeutics, Inc. (Nasdaq: CVTX) for $20.00 per share in cash. Smart Investors Are Quietly Loading Up on These “Dividend Legends” If...
Published:
Last Updated:
Biogen Idec Inc. (NASDAQ: BIIB) is set to report earnings on Friday morning. What many investors probably want to know is if these results — or more importantly its guidance — show that this...
Published:
Last Updated:
There may be some speculation that drug giant Pfizer Inc. (NYSE: PFE) is looking at expansion through acquisitions. The FT reported that the world’s largest pharmaceutical company is willing to...
Published:
Last Updated:
It is getting pretty thin in major analyst coverage as firms are encouraged to go easy on major year-end calls barring anything unexpected. These are the top analyst upgrades, downgrades, and new...
Published:
Last Updated:
These are the top pre-market upgrades and positive analyst calls we have seen from Wall Street this Monday morning: Altria (NYSE: MO) Raised to Overweight at JPMorgan. Best Buy (NYSE: BBY) Raised to...
Published:
Last Updated:
It seems that short sellers have no real direction in the major NASDAQ biotech stocks from mid-November to late-November. Generally you see a pattern. This month the only pattern seems to be one...
Published:
Gilead Sciences Inc. (NASDAQ: GILD) has just issued its third quarter earnings at $0.52 net EPS and $0.55 non-GAAP EPS and $1.37 billion in revenue. First Call had estimates at $0.49 non-GAAP EPS...
Published:
Last Updated:
Gilead Sciences Inc. (NASDAQ: GILD) is trading down this morning. Goldman Sachs maintained its buy rating on the stock, but took down its price target to $58 from $59. This report is after a...
Published:
Last Updated:
There are surprisingly few analyst calls today, but these are some of the top positive calls and upgrades with more than two hours to the market open: Diebold (DBD) Raised to Buy at Wedbush Morgan....
Published:
These are not all of the Downgrades or negative analyst calls seen this morning but these are some of the top calls seen this Friday morning: Best Buy (NYSE: BBY) Cut to Outperform from Top Pick at...
Published:
These are ten of the analyst calls we are seeing early this Thursday morning in early bird pre-market trading hours: American International Group (NYSE: AIG) raised to Buy at Citigroup. Bare...
Published:
Gilead Sciences, Inc. (NASDAQ: GILD) posted results after the close today. Its Q1 revenues surged to $1.26 billion and non-GAAP earnings was $522.1 million, or $0.54 EPS. First Call had estimates...
Published:
Last Updated: